Discontinuation of Heart Failure Pharmacotherapy in Older Adults With Frailty
Journal of the American Heart Association · 17.03.2026 · 15 (6)
DOI: 10.1161/jaha.125.047638 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 17.03.2026. Verfasst von Ryo Nakamaru und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine Kyorin University School of Medicine Tokyo Japan. Hauptthemen laut MEDLINE: Heart Failure, Frailty, Frail Elderly, Cardiovascular Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Herzinsuffizienz, Gerontologische Pflege
Abstract (Originalsprache)
Background
Guideline‐directed medical therapy (GDMT) improves outcomes in heart failure irrespective of frailty status. Nevertheless, the magnitude of frailty‐associated discontinuation of GDMT remains insufficiently studied. We aimed to quantify 12‐month discontinuation rates of GDMT across frailty strata.
Methods
This retrospective cohort study used a nationwide insurer‐based database. We identified patients aged ≥65 years who were hospitalized for heart failure between 2014 and 2022 and newly initiated on at least 1 GDMT at discharge, including angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers/angiotensin receptor‐neprilysin inhibitors, β‐blockers, mineralocorticoid receptor antagonists, or SGLT2is (sodium‐glucose cotransporter‐2 inhibitors). Discontinuation was defined as a gap of 60 days without a prescription following the expected completion of the dispensed supply. The cumulative incidence of GDMT discontinuation within 12 months was estimated according to Hospital Frailty Risk Score, with death treated as a competing risk.
Results
We analyzed 33 155 patients (mean age: 83.2 years, women: 53.0%). The initiating rates were as follows: angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers/angiotensin receptor‐neprilysin inhibitors 48.3% (N=16 025), β‐blockers 54.9% (N=18 197), mineralocorticoid receptor antagonists 44.1% (N=14 608), and SGLT2is 5.9% (N=1948). The Hospital Frailty Risk Score categories were as follows: low (33.2%), intermediate (47.1%), and severe (19.7%). Discontinuation rates increased with frailty severity: angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers/angiotensin receptor‐neprilysin inhibitors 27.5%, 39.0%, 45.5% (for low, moderate, and high Hospital Frailty Risk Score, respectively, P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine Kyorin University School of Medicine Tokyo Japan.
- Department of Healthcare Quality Assessment The University of Tokyo Graduate School of Medicine Tokyo Japan.
- Department of Health Data Science, Graduate School of Data Science Yokohama City University Yokohama Kanagawa Japan.
- Department of Cardiology Keio University School of Medicine Tokyo Japan.
ORCID-Profile: Ryo Nakamaru, Shiori Nishimura, Kyohei Daigo, Shun Kohsaka
Zitieren
APA
Nakamaru, R., Nishimura, S., Kumamaru, H., Daigo, K., Walsh, K. M., & Kohsaka, S. (2026). Discontinuation of Heart Failure Pharmacotherapy in Older Adults With Frailty. Journal of the American Heart Association, 15(6). https://doi.org/10.1161/jaha.125.047638
Vancouver
Nakamaru R, Nishimura S, Kumamaru H, Daigo K, Walsh KM, Kohsaka S. Discontinuation of Heart Failure Pharmacotherapy in Older Adults With Frailty. Journal of the American Heart Association. 2026;15(6). doi:10.1161/jaha.125.047638
BibTeX
@article{Nakamaru2026,
author = {Nakamaru, Ryo and Nishimura, Shiori and Kumamaru, Hiraku and Daigo, Kyohei and Walsh, Kayo M and Kohsaka, Shun},
title = {Discontinuation of Heart Failure Pharmacotherapy in Older Adults With Frailty},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {6},
doi = {10.1161/jaha.125.047638}
}
EUVIMED